We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Tecentriq “continues to demonstrate benefits across multiple cancer types and therefore remains a meaningful treatment option for many patients,” Roche said. Read More
The FDA’s Oncology Center for Excellence is scrutinizing Accelerated Approvals granted for cancer indications in an initiative that’s led to multiple indication withdrawals by companies whose late-stage trials failed to meet primary endpoints. Read More